Atopic dermatitis management with tacrolimus ointment (Protopic®)

Journal of Dermatological Treatment

Volumn 14, Issue SUPPL. 1, 2003, Pages 5-16

  Kapp, Alexander ^a   Allen, B R ^b   Reitamo, S ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Atopic dermatitis; Clinical management; Efficacy; Tacrolimus ointment; Tolerability

Indexed keywords

IMMUNOMODULATING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; TACROLIMUS;

ADULT; ATOPIC DERMATITIS; BURNING SENSATION; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HUMAN; LONG TERM CARE; MULTICENTER STUDY; OINTMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN ATROPHY; SKIN CANCER; SKIN INFECTION; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OINTMENTS; TACROLIMUS;

EID: 0141926677     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: 10.1080/1361241031002375     Document Type: Conference Paper

References (41)

1. Hanifin JM, Rajka G, Diagnostic features of atopic dermatitis. Acta Dermatovener (Stockh) (1980) 92: S44-7.
2. Leung DY, Hanifin JM, Charlesworth EN et al, Disease management of atopic dermatitis: a practice parameter. Ann Allergy Asthma Immunol (1997) 79: 197-211.
3. Kino T, Hatanaka H, Hashimoto M et al, FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) (1987) 40: 1249-55.
4. Fleischer AB, Jr, Treatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorticosteroidal therapy. J Allergy Clin Immunol (1999) 104: S126-30.
5. Leung DYM, Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol (2000) 105: 860-76.
6. Wollenberg A, Sharma S, von Bubnoff D et al, Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol (2001) 107: 519-25.
7. Diepgen TL, Is the prevalence of atopic dermatitis increasing? In: Williams HC, ed. Atopic dermatitis. The epidemiology, causes and prevention of atopic eczema. Cambridge: Cambridge University Press, 2000: 96-109.
8. Zheng PS, Lavker RM, Lehmann P, Kligman AM, Morphologic investigations on the rebound phenomenon after corticosteroid-induced atrophy in human skin. J Invest Dermatol (1984) 82: 345-52.
9. Goerz G, Lehmann P, Topical treatment with corticosteroids. In: Ruzicka T, Ring J, Przybilla B, eds. Handbook of Atopic Eczema. Berlin: Springer Verlag, 1991: 375-90.
10. Brazzini B, Pimpinelli N, New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol (2002) 3: 47-58.
11. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E, and the Tacrolimus Ointment Study Group, Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol (2001) 44: S28-38.
12. Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M, and the Tacrolimus Ointment Study Group, A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol (2001) 44: S47-57.
13. Reitamo S, Rustin M, Ruzicka T et al, for the European Tacrolimus Ointment Study Group, Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 109: 547-55.
14. Reitamo S, van Leent EJM, Ho V et al, for the European/Canadian Tacrolimus Ointment Study Group, Efficacy and safety of tacrolimus ointment compared with hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol (2002) 109: 539-46.
15. Reitamo S, for the European Tacrolimus Ointment Study Group, 0.1% Tacrolimus ointment is significantly more efficacious than a steroid regimen in adults with moderate to severe atopic dermatitis. 12th Congress of the European Academy of Dermatology and Venereology, St. Julian's, Malta, 27 February-1 March: Poster presentation PP1-28.
16. Reitamo S, Wollenberg A, Schopf E et al, for the European Tacrolimus Ointment Study Group, Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol (2000) 136: 999-1006.
17. Kang S, Lucky AW, Pariser D et al, and the Tacrolimus Ointment Study Group, Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol (2001) 44: S58-64.
18. Remitz A, for the European Tacrolimus Ointment Study Group, Superior flare prevention with 0.1% tacrolimus ointment in adult patients with moderate to severe atopic dermatitis. Proceedings from the 11th Congress of the European Academy of Dermatology and Venereology, Prague, Czech Republic, 2-6 October 2002.
19. Breuer K, Häussler S, Kapp A, Werfel T, Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol (2002) 147: 55-61.
20. Hank PJ, Leung DYM, Tacrolimus (FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis? J Allergy Clin Immunol (2001) 107: 391-2.
21. Drake L, Prendergast M, Maher R et al, The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol (2001) 44: S65-72.
22. Rico MJ, Lawrence I, Tacrolimus ointment for the treatment of atopic dermatitis: clinical and pharmacologic effects. Allergy Asthma Proc (2002) 23: 191-7.
23. Alaiti S, Kang S, Fiedler VC et al, Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol (1998) 38: 69-76.
24. Undre NA, Green A, Harper J et al, Tacrolimus pharmacokinetics in paediatric patients with moderate to severe atopic dermatitis after single and repeated application. Ann Dermatol Venereol (2002) 129: Abstract P0273.
25. Fujisawa, data on file.
26. Soter NA, Fleischer AB, Webster GF et al, Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol (2001) 44: S39-46.
27. Vieluf D, Ruzicka T, Complications and diseases associated with atopic eczema. In: Ruzicka T, Pryzbilla B, eds. Handbook of atopic eczema. Berlin: Springer Verlag, 1991: 54-79.
28. Caro I, Gordon KB, West DP, and the Tacrolimus Ointment Study Group et al, Long-term safety of topically applied tacrolimus ointment in adult patients with atopic dermatitis. American Academy of Dermatology 60th Annual Meeting, New Orleans, LA, USA, 22-27 February 2002: Poster presentation P111.
29. Paller A, Hanifin J, Eichenfield L et al, Tacrolimus ointment monotherapy is a safe and effective treatment for atopic dermatitis long-term (more than 3 years). American Academy of Dermatology 61st Annual Meeting, San Francisco, CA, 21-26 March 2003: Poster presentation P24.
30. Reitamo S, Rissanen J, Remitz A et al, Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol (1998) 111: 396-8.
31. Naylor M, Elmets CA, Rico MJ, Zheng S, and the Tacrolimus Ointment Study Group, Treatment with topical tacrolimus is not associated with an increase in non-melanoma skin cancers. The American Academy of Dermatology 60th Annual Meeting, New Orleans, LA, USA, 22-27 February 2002: Poster presentation P18.
32. Frieling UM, Schaumberg DA, Kupper TS et al, A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician's health study. Arch Dermatol (2000) 136: 179-84.
33. Aly R, Bacteriology of atopic dermatitis. Acta Dermatovener (Stockholm) (1980) 92: S16-8.
34. Pournaras CC, Lubbe J, Saurat JH, Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (FK506). J Invest Dermatol (2001) 116: 480-1.
35. Remitz A, Kyllönen H, Granlund H, Reitamo S, Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol (2001) 107: 196-7.
36. Stalder JF, Fleury M, Sourisse M et al, Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol (1994) 131: 536-40.
37. Fujisawa. Summary of product characteristics. Protopic (tacrolimus) 0. 03% and 0.1% ointment. April 2002.
38. Novartis. Elidel (pimecrolimus) cream 1% prescribing information. December 2001.
39. Sato K, Sugibayashi K, Morimoto Y, Species differences in percutaneous absorption of nicorandil. J Pharm Sci (1991) 80: 104-7.
40. Barry B, Dermatological formulations: percutaneous absorption. In: Drugs and the Pharmaceutical Sciences Vol 18. New York/Basel: Marcel Dekker Inc., 1983: 138-45.
41. Stiehm ER, Roberts RL, Kaplan MS et al, The effect of tacrolimus ointment on the immune system of children aged 2-12. American Academy of Dermatology 61st Annual Meeting, San Francisco, CA, 21-26 March 2003: Poster presentation P545.